Immunotherapy Coverage from Every Angle

Published Medical Literature

Early-Phase Study of KITE-585 in Resistant Multiple Myeloma
Case Report: Older Woman With Metastatic Bladder Cancer Responds to Pembrolizumab
ERBB2-Positive Breast Cancer: How Does T-DM1 Measure Up Against Standard Neoadjuvant Treatment?
Stem Cell–Derived Dendritic Cells With Radiotherapy Under Study in Preclinical Breast Cancer Models
Is Isatuximab Plus Carfilzomib/Dexamethasone the New Standard of Care in Relapsed Multiple Myeloma?
CheckMate 274: Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma
Cohort 2 of KEYNOTE-023: Pembrolizumab-Based Combination for Resistant Myeloma
Avelumab in Electrochemotherapy-Resistant Merkel Cell Carcinoma: Case Report
RATIONALE 304: Tislelizumab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer
Adjuvant Treatment of Early-Stage Breast Cancer: T-DM1 Versus Paclitaxel Plus Trastuzumab
Enfortumab Vedotin-ejfv Under Study in Cisplatin-Ineligible Urothelial Carcinoma
CLL14 Trial: Impact of Venetoclax Plus Obinutuzumab Treatment on Health-Related Quality of Life
Isatuximab Under Study in Daratumumab-Refractory Multiple Myeloma
Rare Case of Bladder Metastasis of Kidney Cancer: Potential Role of Genomic Analysis
Feasibility Study in Upper Tract Urothelial Cancer: Neoadjuvant Pembrolizumab Before Surgery
Proof-of-Concept Trial of Chemotherapy Plus Immune Checkpoint Inhibitor in Unresectable NSCLC
Can Combination of Targeted Therapy and Immunotherapy Improve Surgical Outcomes in Renal Cell Carcinoma?
Adding Stereotactic Body Radiotherapy to Immunotherapy for Early-Stage NSCLC
Does Ibrutinib Pretreatment Reduce the Risk of Obinutuzumab-Related Infusion Reactions in CLL?
Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study
CARTITUDE-1 Trial: Targeting BCMA With CAR T-Cell Therapy for Myeloma
Combination Therapy for Metastatic Urothelial Bladder Carcinoma With FGFR3 Mutation: A Case Study
Metastatic Kidney Cancer: Targeted Therapy Plus Immune Checkpoint Inhibition
Interim Analysis of Phase III Trial of Combination Therapies for Resistant Myeloma
Identifying Bladder Cancer Subtypes by Metabolic Characteristics: Therapeutic Implications
Medicare-Insured Patients With Advanced Lung Cancer: Does First-Line Immunotherapy Improve Survival?
Standard Versus Escalated Dose of Ofatumumab in Chemoimmunotherapy Regimen for CLL
Adjuvant Nivolumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
Camrelizumab Treatment in Upper Tract Urothelial Carcinoma: Case Report
Locally Advanced Basal Cell Carcinoma: Use of Cemiplimab-rwlc After Hedgehog Inhibitor Therapy
ORIENT-12 Trial: Sintilimab Plus Standard Chemotherapy for Metastatic Lung Cancer
Mixed Results With Rucaparib in ATLAS Trial in Metastatic Urothelial Cancer
Do Trial Findings Translate to Real-World Treatment Success in Metastatic Kidney Cancer?
CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma
Resistant Urothelial Carcinoma: Organ-Specific Response to Pembrolizumab
Nivolumab for Sarcomatoid Renal Cell Carcinoma With Metastases: Case Report
Neoadjuvant Combination Immunotherapy for Operable Lung Cancer: NEOSTAR Trial Update
Breast Tumor Microenvironment: Differences in Black Women?
Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report
AR-V7–Positive Prostate Cancer: Phase II Trial of Combination Immunotherapy
Case of Therapy-Related AML and Myeloma: Decitabine/Venetoclax and Daratumumab
Do Men and Women With Urinary Bladder Cancer Respond Differently to BCG Immunotherapy?
TRAXAR Trial: Adding Novel Monoclonal Antibody to Axitinib in Advanced Kidney Cancer
Eomesodermin: A Master Regulator of CD8-Positive T Cells in CLL?
KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer
TP53-Mutated Bladder Cancer: Identifying Patients Who May Benefit From Immunotherapy
Immune Checkpoint Inhibitors and Kidney Cancer: Immune-Related Adverse Events and Outcomes
First-Line Pembrolizumab Monotherapy in Advanced Non–Clear Cell Renal Cell Carcinoma
Case Study: Immunomodulatory Mechanism and Antimyeloma Effect of Daratumumab
IMWG Offers Updated Recommendations for Managing Myeloma-Related Bone Disease
Do Sex-Specific Hormones Influence Outcomes With Immunotherapy for Kidney Cancer?
Can Osimertinib Plus Bevacizumab Improve Outcomes in Advanced EGFR T790M–Mutated Lung Cancer?
Daratumumab-Based Regimens and Minimal Residual Disease in Patients With Myeloma
CheckMate 9LA: First-Line Immunotherapy Plus Chemotherapy in NSCLC
Plasma Cells and Immune Responsiveness in Black Men With Prostate Cancer
Daratumumab-Based Therapy for Newly Diagnosed Myeloma: Patient-Reported Outcomes From MAIA Trial
Smoking Behavior in Patients With Early-Stage NSCLC Enrolled in Clinical Trial
Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks
Ibrutinib-Refractory CLL: Focus on B Leukemic Cells
Preferred Treatment for Invasive Bladder Cancer: Intravesical Immunotherapy or Radical Cystectomy?
Neoadjuvant Chemoimmunotherapy for Resectable Stage IIIA NSCLC
Gemogenovatucel-T Immunotherapy for Ovarian Cancer Maintenance
Adding ErbB Inhibitor to Standard Chemotherapy for HER2-Positive Breast Cancer
Toxicity Associated With Concomitant Ruxolitinib and Avelumab in Merkel Cell Carcinoma
Intravesical Nadofaragene Firadenovec in Non–Muscle Invasive Bladder Cancer
Ramucirumab Plus Docetaxel in Urothelial Carcinoma: Patient-Reported Outcomes From RANGE Trial
Merkel Cell Carcinoma and Interstitial Lung Disease: Case Report on Use of Pembrolizumab
Combining Novel Monoclonal Antibody With Radiotherapy for NSCLC
Is Immunotherapy Safe for Patients With Myeloma and HBV Infection?
Pembrolizumab Plus T-Cell Inducer Under Study in Triple-Negative Breast Cancer
Extended Follow-up From KEYNOTE-426: Pembrolizumab Plus Axitinib in Kidney Cancer
Atezolizumab Plus VEGF Inhibition in Stage IV Lung Cancer
Can Ibrutinib Enhance CAR T-Cell Production for Patients With CLL?
Combining Tivozanib and Nivolumab in Advanced Renal Cell Carcinoma
Is Immunotherapy Combination Effective as Salvage Treatment in Metastatic Renal Cell Carcinoma?
Long-Term Treatment Strategy for Myeloma: Optimal Selections Based on Stage
Novel PD-1 Antibody Shows Activity in Advanced Lung Cancer
Presence of Immune Checkpoint Markers Identified in Cutaneous Angiosarcoma
Immune Checkpoint Inhibition Among Patients With Dermatologic and Hematologic Cancers
Trastuzumab Monotherapy for Older Patients With HER2-Positive Breast Cancer
Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma
Venetoclax Plus Rituximab in Relapsed CLL: Genomic Complexity and Outcomes
Study Explores Adoptive Cell Therapy for Refractory NSCLC
Targeting Bladder Carcinoma in Situ With Novel Gene Therapy
Multisite Progression of Merkel Cell Carcinoma and Simultaneous Immune-Related Adverse Events
DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma
Combination Regimen Under Study in Metastatic Urothelial Carcinoma
Combination Immunochemotherapy in Locally Advanced or Metastatic NSCLC
Therapeutic Update in AML: Genomic Assessment Is Key
COVID-19 and Multiple Myeloma: Update From Stockholm
Study Explores Potential Prognostic Indicators for Papillary Thyroid Carcinoma
Triple-Negative Breast Cancer: Mixed 19-Peptide Vaccine Monotherapy
Integrin Inhibitor Under Study as Targeted Therapy for Ovarian Cancer
Potential Biomarker Investigated for Merkel Cell Carcinoma
Selecting Initial Therapy in NSCLC: First Step Is Histology
How Comorbidities May Affect Response to Idelalisib-Based Therapy in CLL
Fixed-Duration Combination Regimen Under Study in CLL
Response to Neoadjuvant Immunotherapy for Rectal Cancer: Case Series
Can Immunoglobulin Expression Predict Survival in Patients With AML?
Durvalumab in Advanced Lung Cancer: Final Overall Survival Data From ATLANTIC Trial
Case of Tumor-Lysis Syndrome After Combination CLL Therapy
Phase II Trial Focuses on Isatuximab for Resistant Myeloma
Long-Term Outcomes With Pembrolizumab for NSCLC and Brain Metastases
Real-World Data From Czech Study Group on CD20 Antibody Plus Chemotherapy for CLL
Quality of Life During Pembrolizumab Treatment for Metastatic Triple-Negative Breast Cancer
Subcutaneous Versus Intravenous Pertuzumab/Trastuzumab in Early Breast Cancer: Patient Perspective
Novel Chimeric Monoclonal Antibody Under Study in Metastatic Colorectal Cancer
Novel Antibody-Drug Conjugate Under Study in Platinum-Sensitive Ovarian Cancer
Phase III Trial of Triplet Regimen for HER2-Positive Metastatic Breast Cancer
First-line Osimertinib and Bevacizumab Treatment in Metastatic EGFR-Mutant Lung Cancer
Combination Therapy of Vaccine and Durvalumab in Advanced Ovarian Cancer
First-in-Human Phase I Trial of Novel Vaccine in Metastatic Prostate Cancer
Combination of Abemaciclib, Pembrolizumab, and Anastrozole in Metastatic Breast Cancer
Update on Role of Subcutaneous Daratumumab in Multiple Myeloma
Pneumonitis in Patients Treated With Chemotherapy or Immunotherapy
Response of Early-Stage Colon Cancer to Neoadjuvant Immunotherapy
Safety of Combination Triplet for Lung Cancer in KEYNOTE-189
Pomalidomide-Based Therapy for Multiple Myeloma: Results From MM-014 Trial
Is Proteome Instability a Treatment Opportunity in Mismatch Repair–Deficient Colorectal Cancers?
Tumor-Infiltrating Lymphocytes in Metastatic Lung Cancer
Upfront FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: TRIBE2 Trial Update
Measles Virus Vaccine Under Study in Multiple Myeloma
Head-to-Head Trial Compares Bevacizumab/Platinum-Based Regimens in Recurrent Ovarian Cancer
Rare Case of Dual Multiple Myeloma and AML: Combination Therapy Active for Both
Nivolumab Prior to Surgery in Patients With Merkel Cell Carcinoma
Biomarkers May Predict Sensitivity to Combined PARP and PD-1 Inhibition in Ovarian Cancer
New Role Explored for Lenalidomide: With Chemotherapy for Older Patients With AML
Chemoimmunotherapy vs Chemotherapy in CLL: 5-Year Follow-up of Complement 1 Trial
CENTAURUS Trial: Daratumumab Monotherapy for Smoldering Multiple Myeloma
Durvalumab in Unresectable NSCLC: Are Outcomes Affected by PD-L1 Expression?
Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma
Rocapuldencel-T Plus Sunitinib in Metastatic Renal Cell Carcinoma
CAR T-Cell Strategy for Myeloma: Two Targets, Fewer Relapses
Pembrolizumab With Bevacizumab in Metastatic Kidney Cancer
Use of Duvelisib After Ofatumumab in Resistant CLL/SLL
Pembrolizumab Plus Chemotherapy for Metastatic Lung Cancer: Quality-of-Life Outcomes
Treatment Potential of CAR-Transduced Natural Killer Cells in CLL
Phase I Trial of Immunotherapy Plus Radiotherapy for Advanced Melanoma
Pathologic Complete Response With Pembrolizumab for Triple-Negative Breast Cancer
Circulating Tumor DNA Assays and Response to Melanoma Treatment
Meta-analysis Supports Maintenance Therapy for Reducing CLL Progression
CLL-Stereotyped Immunoglobulin Gene Rearrangements in Normal B-Cell Subsets
GVAX Vaccine With Cyclophosphamide and Pembrolizumab in Advanced Colorectal Cancer
Daratumumab-Based Combination Therapy in Newly Diagnosed Myeloma: GRIFFIN Study Update
Adding Pemetrexed to Bevacizumab in Advanced Nonsquamous Lung Cancer
Sequential Combination Therapy for Chronic Lymphocytic Leukemia
Predicting Relapse of Stage III Melanoma Using Circulating Tumor Cells
Tumor Mutation Burden in Metastatic NSCLC: Predictive of Response to Pembrolizumab?
Moxetumomab Pasudotox Therapy Under Study in Resistant Hairy Cell Leukemia
Does Immunotherapy Offer Survival Advantage in Resected Cutaneous Melanoma?
Early Research Findings on CAR T-Cell Therapy in Resistant Multiple Myeloma
Early-Phase Study of Acalabrutinib Plus Obinutuzumab in CLL
AMG 420 T-Cell Therapy Induces Responses in Resistant Multiple Myeloma
Potential Effect of Antigen Drive on T-Cell Repertoire in CLL
Second-Line Gemcitabine With Dual Antibody Therapy for ERBB2-Positive Metastatic Breast Cancer
Does Adding Cetuximab to Radiotherapy Improve Survival in Unresectable Lung Cancer?
Targeting B-Cell Maturation Antigen in Resistant Multiple Myeloma
Locally Advanced Nasopharyngeal Cancer: Induction Therapy With Nimotuzumab Plus Chemotherapy
Use of Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma
Immune-Related Adverse Events and Recurrence-Free Survival in Melanoma
Responses to Novel Drug Combination Among Patients With Multiple Myeloma
Quality of Life of Melanoma Survivors Treated With Pembrolizumab
Monoclonal Antibody Combination Under Study in Rare Metastatic Kidney Cancer
Is Combined Checkpoint Blockade Effective in Treating Uveal Melanoma?
Everolimus Plus Bevacizumab in Recurrent Ovarian Cancer
Combination of Rituximab and High-Dose Methylprednisolone for High-Risk Patients With CLL
BCMA-Targeted Immunoconjugate for Resistant Multiple Myeloma
Role of Bevacizumab in Patients With Advanced NSCLC With Liver Metastases
Adding Bevacizumab to Platinum-Based Chemotherapy in Head/Neck Squamous Cell Carcinoma
Does Pathologic Response to Immunotherapy Differ in Australian and European Patients With Melanoma?
Cell Death Pathways in Targeted Therapy for Renal Cell Carcinoma
Shedding Light on Elotuzumab’s Mechanism of Action in Treating Myeloma
Can Immunotherapy Improve Response to Salvage Chemotherapy in Head/Neck Cancer?
Case Studies Focus on Possible Link Between Nivolumab and Pericardial Effusion
Personalized Algorithm to Predict Response to Immunotherapy for Melanoma
FOLFOXIRI Plus Panitumumab in First-Line Treatment of Colorectal Cancer
Can Gut Microbiota Influence Response to Immunotherapy in Patients With Melanoma?
Chemoradiotherapy Plus Avelumab in Advanced Head/Neck Cancer
IMMUNED Trial: Neoadjuvant Immunotherapy for Stage IV Melanoma With No Evidence of Disease
First-in-Class Pegilodecakin Plus Immunotherapy Under Study in Lung Cancer
Olaparib Plus Durvalumab Treatment of BRCA-Mutant Ovarian Cancer: MEDIOLA Trial
BEACON CRC Trial: Improved Outcomes With Triplet Therapy in Colorectal Cancer
JAVELIN Solid Tumor Trial: Avelumab Monotherapy for Metastatic Kidney Cancer
Adjuvant Trastuzumab and Cardiac Toxicities in Patients With Breast Cancer
KATE2 Trial: Updated Overall Survival With Immunotherapy Combination in Advanced Breast Cancer
Bevacizumab Plus Erlotinib or Erlotinib Alone in EGFR-Mutated Lung Cancer
Efficacy of Nivolumab in Patients With Advanced Ocular or Mucosal Melanoma
Nivolumab Plus Ipilimumab in Advanced Kidney Cancer: CheckMate 214 Update
Long-Term Outcomes With Nivolumab Plus Ipilimumab for Melanoma Brain Metastases
Does the Mode of Disease Progression Affect Outcomes in CLL?
Long-Term Phase III Trial Results With Adjuvant Ipilimumab for Advanced Melanoma
Cancer-Testis Antigens: Immunotherapy Targets for Merkel Cell Carcinoma?
Long-Term Survival With Nivolumab in Advanced Lung Cancer
Why Do Some Patients With Melanoma Fail to Respond to Immunotherapy?
Pembrolizumab for Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma: A Case Study
Final Results of MARIANNE Trial of T-DM1 in HER2-Positive Advanced Breast Cancer
Phase III Trial Shows Venetoclax/Obinutuzumab Active in First-Line Treatment of CLL
New Outcome Measure Posited for Immunotherapy in Advanced Melanoma
Early Results With Cirmtuzumab/Ibrutinib Therapy for CLL
Targeting Leukemic Stem Cells in CML With Immunotherapy
Immunotherapy Under Study in Resistant CLL: ZUMA-8 Trial
Pamiparib Plus Tislelizumab Being Studied Further in Ovarian Cancer
Daratumumab and Lenalidomide/Dexamethasone in Multiple Myeloma MAIA Trial
Nivolumab for Advanced Melanoma: 5-Year Survival
Two Phase III Trials Evaluating Daratumumab-Based Therapies for Multiple Myeloma
Dosing Schedule for Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
Niraparib Plus Pembrolizumab in Recurrent Platinum-Resistant Ovarian Carcinoma
Case Study of ‘Long-Lasting’ Response to Nivolumab in Patient With BRCA1 Mutation
Is Pembrolizumab of Benefit in Oligometastatic Lung Cancer After Local Ablative Therapy?
Bevacizumab for Ovarian Cancer: Final Overall Survival Analysis of GOG-0218
Nivolumab for Advanced Lung Cancer: 5-Year Survival
Pembrolizumab Therapy for Inoperable Case of Squamous Cell Carcinoma
Adjuvant Trastuzumab for HER2-Positive Breast Cancer: Results of Two Phase III Trials
IMpower130 Supports Atezolizumab Inclusion in Stage IV Lung Cancer Therapy
HannaH Trial: Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer
Pinpointing Best Dose of Immunotherapy (AMG 420) in Resistant Myeloma
VALENTINO Study: Comparing Maintenance Therapies in Metastatic Colorectal Cancer
Is Adding Entinostat to Avelumab of Benefit in Treating Advanced Epithelial Ovarian Cancer?
Does Stereotactic Body Radiotherapy Enhance the Effect of Immunotherapy for Lung Cancer?
Melanoma Brain Metastases: Can Nivolumab and Ipilimumab Cross the Blood-Brain Barrier?
First-Line Treatment With Atezolizumab Plus Bevacizumab Versus Sunitinib in Kidney Cancer
CASSIOPEIA Trial: Daratumumab Combination Therapy for Newly Diagnosed Multiple Myeloma
Use of Avelumab in Merkel Cell Carcinoma: Linking Early Response With Overall Survival
Tumor-Infiltrating Immune Cell Characteristics and Recurrence of Clear Cell Kidney Cancer
Meta-analysis of Treatment of Skin Cancers With PD-1/PD-L1 Inhibitors
Niraparib Plus Pembrolizumab in Triple-Negative Breast Cancer: TOPACIO/KEYNOTE-162 Trial
Adding Erlotinib to Bevacizumab in EGFR-Positive Lung Cancer
Immune-Related Adverse Events With Nivolumab: Predicting Outcomes in Kidney Cancer
Phase I Study Findings With bb2121 in Resistant Myeloma
Adding Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC
Long-Term Outcomes With Adjuvant Paclitaxel and Trastuzumab in HER2-Positive Breast Cancer
IV Versus IP Chemotherapy Plus Bevacizumab in Advanced Ovarian Cancer
Predicting Response to Immunotherapy for Kidney Cancer With FDG-PET/CT
Correlation Between Blood and Tumor T-Cell Cytotoxicity May Predict Treatment Effectiveness
Combination Therapy May Be Key to Treating KRAS-Mutant NSCLC
First-Line Combination Therapy in Metastatic Kidney Cancer: Answers and More Questions
Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Immunotherapy for Advanced Lung Cancer: Is Tumor Mutational Burden Linked to Response?
Does Squamous Cell Carcinoma Risk Change With Immunosuppression?
Can a Single Dose of PD-1 Inhibitor Before Surgery Predict Outcomes in Melanoma?
KEYNOTE-426 Trial: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer
Nivolumab/Ipilimumab in Advanced Melanoma: Comparison of Dosing Regimens
KAMILLA Trial: T-DM1 Safety in HER2-Positive Breast Cancer
Tisotumab Vedotin Exhibits Antitumor Activity in Bladder Cancer, Among Other Cancers
Treatment With Avelumab in Resistant Ovarian Cancer
Immunotherapy for Patients With NSCLC and HIV Infection
JAVELIN Renal 101 Trial: Axitinib Plus Avelumab in Kidney Cancer
New Combination Therapy for NSCLC Tested in Phase II Trial
Ovarian Carcinosarcoma: Update on a Rare Malignancy
Dasatinib in CML: Activating Natural Killer Cells
Use of Pembrolizumab in First-Line Treatment of Merkel Cell Carcinoma
Tisotumab Vedotin Exhibits Antitumor Activity in NSCLC, Among Other Cancers
Pembrolizumab Versus Platinum-Based Chemotherapy in Advanced NSCLC
Immunotherapy for Patients With Melanoma and HIV Infection
Patient-Reported Outcomes in Advanced Renal Cell Carcinoma
Tisotumab Vedotin Exhibits Antitumor Activity in Ovarian Cancer, Among Other Cancers
Use of Cetuximab in Multimodality Treatment of Cutaneous Squamous Cell Carcinoma
ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide/Dexamethasone in Resistant Myeloma
Study of Combination Immune Checkpoint Blockade in Stage III Melanoma Halted
Neoadjuvant Pembrolizumab Before Surgery in Muscle-Invasive Bladder Carcinoma
Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC
Combination Immunotherapy in First-Line Treatment of Advanced Kidney Cancer
Use of Pembrolizumab for Active Brain Metastases in Patients With Melanoma
Chemosensitivity Mediator and Immunotherapy Target Identified in Ovarian Cancer
Combination Epacadostat and Pembrolizumab in NSCLC
Clinical Benefits of Cetuximab Versus Cisplatin in HPV-Positive Oropharyngeal Cancer
Safety of Daratumumab in Relapsed or Refractory Multiple Myeloma
Combination of Epacadostat and Pembrolizumab in Advanced Melanoma
Durvalumab With or Without Tremelimumab in Subgroup of Resistant Head and Neck Cancer
Atezolizumab in Metastatic Triple-Negative Breast Cancer: Long-Term Outcomes
JAVELIN Lung 200: Avelumab Versus Docetaxel in Advanced Lung Cancer
Pembrolizumab-Associated Dermatomyositis in a Patient With Melanoma
ELOQUENT-2 Trial: Long-Term Benefits of Triplet Therapy in Multiple Myeloma
Alliance Study: Comparing Neoadjuvant Therapy Approaches in HER2-Positive Breast Cancer
Immunotherapy for Stage III Melanoma: Neoadjuvant vs. Adjuvant
Combining TKIs and Immune Checkpoint Inhibitors in Advanced Kidney Cancer
Do Brain Metastases Affect Outcomes With Immunotherapy?
Choosing Among First-Line Treatments in Advanced Kidney Cancer
MAVORIC Results Support FDA Approval of Mogamulizumab in Cutaneous C-Cell Lymphoma
Case Study Highlights Novel Concurrent Therapy for Cutaneous Squamous Cell Carcinoma
Does Following Induction Therapy With Cetuximab Radiotherapy Improve Outcomes in Head and Neck Cancers?
Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?
ASCO Clinical Practice Guidelines Updates in Advanced HER2-Positive Breast Cancer
Update on Nonsurgical Treatments of Non-Melanoma Skin Cancer
Bevacizumab Plus Immune Checkpoint Inhibition in Renal Cell Carcinoma
Neoadjuvant Chemotherapy Plus Panitumumab in Inflammatory Breast Cancer
Are Patients With Chronic Lymphocytic Leukemia at Risk for Melanoma?
ASCO Guideline Update: Adjuvant Chemotherapy and Targeted Therapy for Breast Cancer
Can Patients With Melanoma Benefit From Antigen-Specific Immunotherapeutic?
Review Features Clinical Challenges of Personalized Treatment in NSCLC
Comparing Trastuzumab Biosimilar and Reference Trastuzumab in HER2-Positive Breast Cancer
Immunotherapy in Multiple Myeloma: Today and Tomorrow
Is Ado-Trastuzumab Emtansine Active in HER2-Mutant Lung Cancer?
Closer Look at Therapeutic Interventional Clinical Trials in Multiple Myeloma
Delayed Skin Reactions Reported With PD-1 Inhibitors
Radiosurgery Plus Immunotherapy in Patients With Brain Metastases From Melanoma
Does Prior Antibiotic Use Affect Treatment Outcomes in Lung Cancer?
Combination Pazopanib Plus Cetuximab Therapy Warrants Further Study
Responses to Immune Checkpoint Inhibitors in Patients With NRAS-Mutant Melanoma
Novel Antibody-Drug Conjugate in Platinum-Resistant Ovarian Cancer
New Guidelines for Treating Metastatic Merkel Cell Carcinoma: Focus on Immunotherapy
Intensified Treatment Approach May Improve Survival in Some Patients With Myeloma
First-Line Avelumab for Metastatic Merkel Cell Carcinoma
Who Does Better on Anti–PD-1 Therapy for Melanoma: Younger or Older Patients?
Is Elotuzumab Monotherapy Beneficial in Patients With Smoldering Multiple Myeloma?
Novel Immunotherapy for Poor-Prognosis Relapsed Multiple Myeloma
Study Sheds Light on Dendritic Cell Subsets in Tonsillar Cancer
Baseline Tumor Size and Prognosis in Pembrolizumab-Treated Melanoma
Immune Stimulant in Combination With Nivolumab for Metastatic Lung Cancer
Efficacy of Immunotherapy for Melanoma: Does Gender Matter?
Noninterventional Study of Lenalidomide Plus Dexamethasone in Resistant Myeloma
Treating Nasopharyngeal Carcinoma With Nivolumab
Efficacy of Immunotherapy for Lung Cancer: Does Gender Matter?
Addition of CAR T-Cell Therapy to Stem Cell Transplantation in Refractory Multiple Myeloma
Health-Related Quality of Life With Pembrolizumab for Advanced Urothelial Cancer
Pilot Clinical Trial of Dendritic Cell Vaccination in Ovarian Cancer
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Updated ASCO Guideline for Use of Bone-Modifying Agents in Multiple Myeloma
Comparison of Nivolumab/Ipilimumab and Sunitinib in Advanced Kidney Cancer
DDR Genes and Response to Checkpoint Blockade in Urothelial Cancer
Durvalumab in Heavily Pretreated Patients With Advanced Lung Cancer
PD-1 Blockade in Advanced Desmoplastic Melanoma
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Long-Term Survival With Nivolumab in Pretreated Patients With Advanced Lung Cancer
Outcomes When Patients With Melanoma Discontinue Nivolumab/Ipilimumab Combination
Genomic Alterations in Clear Cell Renal Cell Carcinoma and Response to Immune Checkpoint Inhibitors
Denosumab Versus Zoledronic Acid for Treating Myeloma With Bone Disease
Continuation of Immunotherapy Beyond Disease Progression in Advanced Melanoma
Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
Are Two Monoclonal Antibodies Better Than One in Advanced Melanoma?
Long-Term Survival With Pembrolizumab for Advanced Melanoma
Nivolumab Versus Ipilimumab in Patients With Resected Advanced Melanoma
Does Small Cell Ovarian Cancer Respond to Immunotherapy?
ASPIRE Trial: Triplet Therapy in Relapsed or Refractory Multiple Myeloma
Gene Discovery May Shed Light on Mechanism of Immunotherapy Resistance
Long-Term Outcomes With Atezolizumab in Metastatic Urothelial Carcinoma
Considering Newer Agents in Managing Relapse in Resistant Myeloma
Axitinib Plus Pembrolizumab in Advanced Kidney Cancer
BCMA as a Therapeutic Target and Biomarker in Multiple Myeloma
Dual HER2 Blockade in Metastatic Breast Cancer
Clinical Practice Update on Bone-Modifying Agents in Patients With Multiple Myeloma
Pertuzumab-Containing Neoadjuvant Regimens in HER2-Positive Breast Cancer
Dual HER2-Targeting Treatments for Postmenopausal Women With Metastatic Breast Cancer
Combination Therapy for Previously Untreated Advanced Lung Cancer
Early Research Studies May Advance the Treatment of Multiple Myeloma
Avelumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer
Novel Antibody Clone for Targeting Multiple Myeloma Cancer Cells
Should Bevacizumab Accompany Adjuvant Chemotherapy in Early-Stage NSCLC?
Long-Term Outcomes With Nivolumab vs. Docetaxel in Advanced Lung Cancer
Safety of Checkpoint Inhibitors Plus Radiotherapy for Metastatic Lung Cancer
Cardiac Effects of Trastuzumab Therapy in Patients With HER2-Positive Breast Cancer
Cost-Effectiveness Comparisons of Treatments for Heavily Pretreated Multiple Myeloma
Can Type of Myeloma Influence Response to Monoclonal Antibodies?
Hair Repigmentation and Response to Immunotherapy for NSCLC
Gene Signature in Predicting Response to Immunomodulatory Derivatives in Myeloma
Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?
Neoadjuvant Combination Therapy for HER2-Positive Primary Breast Cancer
HER2-Targeted Therapy and Breast Reconstruction
Immunotherapy After Chemoradiotherapy for Stage III Lung Cancer
Post-Progression Response to Nivolumab in Advanced Renal Cell Carcinoma
Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC
Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma
Neoadjuvant Ado-trastuzumab Emtansine vs. Trastuzumab in Early Breast Cancer
Lenalidomide Maintenance After Transplantation in Multiple Myeloma
Bevacizumab Plus Novel Monoclonal Antibody in Metastatic Kidney Cancer
Response to Immunotherapy in Patients With ‘Claudin-Low’ Breast Tumors
Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma
Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma
Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study
Combination Treatment With or Without Transplantation in Multiple Myeloma
Comparing Trastuzumab-Based Regimens in Older Women With Early-Stage Breast Cancer
Thyroid Dysfunction in Patients Receiving Immunotherapy for Advanced Kidney Cancer
Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer
Pembrolizumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Adding Pertuzumab to Trastuzumab and Chemotherapy in HER2-Positive Breast Cancer
Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer
Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab
Final Survival Data From TH3RESA Trial in Breast Cancer
Final Overall Survival Data From EMILIA Trial
Early-Phase Trial of Vaccine in NSCLC
Combining Monoclonal Antibodies in HER2-Positive Breast Cancer
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.